SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SIBIA Neurosciences (SIBI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (289)3/5/1999 12:46:00 AM
From: scaram(o)uche  Read Replies (1) of 579
 
from another thread (thanks, Harry!)........

To: Richard Harmon (668 )
From: NeuroInvestment
Thursday, Mar 4 1999 10:00PM ET
Reply # of 669

Rick: (OT on migraine) With SNAP/LLY's drug at least slowed, CoCensys' ganaxolone
useful only for perimenstrual women, and Interneuron's LidoDex probably dead
because of preclinical toxicity issues, Allelix's 5HT 1D and 1F drug (not quite as
ultraselective as SNAP's 5HT-1F only approach) is left standing, and is in Phase II,
data to be out 3Q:99. Regards, Harry
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News